Examining Key Data from the FLAURA2 and MIRAPOSA Trials

A renowned lung cancer pharmacy specialist presents the efficacy and safety data from the phase 3 FLAURA2 trial, emphasizing progression-free survival and overall survival outcomes, and shares additional insights from the MIRAPOSA study.

EP: 1.Exploring EGFR Mutations and Prevalence in Non-Small Cell Lung Cancer

Now Viewing

EP: 2.Examining Key Data from the FLAURA2 and MIRAPOSA Trials

EP: 3.Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice

EP: 4.Exploring Key Insights from the PAPILLON Trial

EP: 5.Common Adverse Reactions to EGFR Therapy

EP: 6.Expert Insights on Managing Amivantamab Infusion Reactions, Dosing, and Medication

EP: 7.Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC

Recently, efficacy and safety data from the phase 3 FLAURA2 trial were published regarding the use of osimertinib alongside chemotherapy in the front-line setting. What are some important points to note from this study, and which patients might benefit from adding chemotherapy to osimertinib?
1. Please include a discussion of both PFS and OS observed in the FLAURA2 study
2. Please discuss the adverse events observed in the monotherapy versus combination therapy group.
The combination of amivantamab and a new 3rd generation EGFR TKI, lazertinib, had new front-line data presented at ESMO 2023, namely the MARIPOSA trial. How was this study designed?
What were the results of the MARIPOSA trial, including efficacy and safety data, and how do you anticipate this data to ultimately impact front-line management of EGFR+ metastatic NSCLC with Ex19del or Ex21 L858R mutations?
Despite FLAURA2 and MARIPOSA data now, what questions remain unanswered in the front-line management?
How do you navigate treatment decisions for EGFR-mutated NSCLC patients with brain metastases, considering CNS penetration of the various EGFR-targeted therapies?